Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;26(10):1267.
doi: 10.1177/1352458520948211. Epub 2020 Aug 7.

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Wallace J Brownlee  1
Affiliations
Comment

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Wallace J Brownlee. Mult Scler. 2020 Sep.
No abstract available

Keywords: COVID-19; multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Dr W.J.B. has received honoraria for educational activities and/or participated in advisory boards for Biogen, Celgene, Merck, Mylan, Novartis, Roche and Sanofi.

Comment on

References

    1. Brownlee W, Bourdette D, Broadley S, et al. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology 2020; 94: 949–952. - PubMed
    1. Dersch R, Wehrum T, Fähndrich S, et al. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult Scler 2020; 26(10): 1264–1266. - PubMed
    1. Wurm H, Attfield K, Iversen A, et al. Recovery from COVID-19 in a B cell-depleted multiple sclerosis patient. Mult Scler 2020; 26(10): 1261–1264. - PMC - PubMed
    1. Meca-Lallana V, Aguirre C, Beatrizdel R, et al. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord 2020; 44: 102306–102306. - PMC - PubMed
    1. Carandini T, Pietroboni AM, Sacchi L, et al. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. Mult Scler J 2020. Epub ahead of print. DOI: 10.1177/1352458520926459. - DOI - PubMed